Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : BNTX save search
BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients
Published: 2021-10-01 (Crawled : 07:00) - globenewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
BNTX | $86.43 0.3% 60K
|
Health Technology
|
| O: -8.06%
H: 3.28%
C: 1.51%
phase 2 immunotherapy therapy cancer colorectal cancer trial
BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma
Published: 2021-06-18 (Crawled : 10:00) - globenewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
|
| O: -1.9%
H: 1.38%
C: 1.21%
BNTX | $86.43 0.3% 60K
|
Health Technology
|
| O: -1.07%
H: 2.45%
C: 0.24%
phase 2 trial
Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2
Published: 2020-12-14 (Crawled : 11:01) - globenewswire.com
PFE A | $25.44 0.2% 4.4M
|
Health Technology
|
| O: 1.22%
H: 0.1%
C: -5.79%
BNTX | $86.43 0.3% 60K
|
Health Technology
|
| O: -0.53%
H: 0.29%
C: -14.5%
covid vaccine phase 3 phase 1 phase 2 germany
Gainers vs Losers
| 83% | 17% |
Top 10 Gainers
AGBA | News | $1.37 242.5% 76M
|
Finance
EGOX | $0.0835 131.94% 160M
|
ZCMD | $2.18 50.35% 24M
|
Commercial Services
CHRO | $1.73 41.22% 46K
|
n/a
RWOD | $10.61 32.68% 5.1M
|
n/a
NVFY | $2.77 31.28% 2.2M
|
Consumer Durables
AULT | $0.3174 31.1% 28M
|
Manufacturing
WISA 4 | $7.11 20.71% 4.7M
|
Electronic Technology
MCB 4 | $39.53 19.43% 88K
|
Finance
LIFW | News | $0.99 19.26% 800K
|
Administrative and Support and ...
Your saved searches
Save your searches and get alerts when important news are released.